Advertisement


Eric Roeland, MD, and Timothy E. Quill, MD, on the Debate Over Physician-Assisted Death

2016 ASCO Annual Meeting

Advertisement

Eric Roeland, MD, of the University of California, San Diego, and Timothy E. Quill, MD, of the University of Rochester Medical Center, discuss the debate on whether physician-assisted death should be a legally available option at the end of life when neither palliative nor hospice care is satisfactory.



Related Videos

Hepatobiliary Cancer

Ghassan K. Abou-Alfa, MD, on Sorafenib and Doxorubicin for Advanced Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses findings of this phase III study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (Abstract 4003).

Global Cancer Care

Rakesh Chopra, MD, and Mary Gospodarowicz, MD, on The Indian Perspective of the Current State of Cancer Research and Treatment

Rakesh Chopra, MD, of the Artemis Health Institute, and Mary Gospodarowicz, MD, of Princess Margaret Hospital, discuss oncology from an international point of view.

Prostate Cancer

Celestia S. Higano, MD, and Chris Parker, MD, on the PROMIS Study of Elevated PSA

Celestia S. Higano, MD, of the University of Washington, and Chris Parker, MD, of the Royal Marsden Hospital, discuss findings from this confirmatory study evaluating the accuracy of MRI and TRUS biopsy in men with an elevated PSA (Abstract 5000).

Breast Cancer
Gynecologic Cancers

Lisa A. Carey, MD, and Tuya Pal, MD, on BRCA Carriers: The Disparities in Management

Lisa A. Carey, MD, of the University of North Carolina, and Tuya Pal, MD, of H. Lee Moffitt Cancer Center & Research Institute, discuss the racial disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors (Abstract LBA1504).

Prostate Cancer

A. Oliver Sartor, MD, and Celestia S. Higano, MD, on Findings of the FIRSTANA Trial in Prostate Cancer

A. Oliver Sartor, MD, of Tulane University, and Celestia S. Higano, MD, of the University of Washington, discuss findings from this phase III study on cabazitaxel vs docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (Abstract 5006).

Advertisement

Advertisement




Advertisement